Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02904226 · ClinicalTrials.gov registry record · Phase 1
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
A Phase 1 study, sponsored by Jounce Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 242
- Enrollment target
NCT02904226: Completed Phase 1 study, sponsored by Jounce Therapeutics.
NCT02904226 is a Phase 1 study that has completed, run by Jounce Therapeutics. The registered enrollment target is 242 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02904226, a Phase 1 study, has completed, sponsored by Jounce Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 242 participants
- Enrollment target
Study Summary
JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG JTX-2011
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2016-08 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02904226
The ClinicalTrials.gov registry entry for NCT02904226 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jounce Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02904226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02904226 about?
NCT02904226 is a clinical study titled "JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors". JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase ...
What is the current status of trial NCT02904226?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 242 participants. The study started on 2016-08. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT02904226?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), JTX-2011 (DRUG).
Who is sponsoring clinical trial NCT02904226?
This trial is sponsored by Jounce Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.